1. Introduction {#sec1}
===============

Type 2 diabetes (T2D) is a chronic metabolic disorder, which results from impaired insulin secretion and action in target tissues \[[@B1], [@B2]\]. Currently, the incidence of T2D is increasing worldwide \[[@B3]\]. And it is reported that there will be 280 million cases suffering from T2D in 2011 \[[@B4]\]. The prevalence trend is considered to be ascribed to genetic variants and environmental factors such as sedentary lifestyle, obesity \[[@B3], [@B5]--[@B7]\]. Despite the foundational evidence of the mechanism underlying T2D is far from being clear, great contributions have been made to address this health concern.

The variants of some critical genes are determined to contribute to T2D development. The TCF7L2 gene of transcription factor 7-like 2 commonly variant in individuals confers the risk of suffering from T2D \[[@B8]\]. Other genes that have expression variation in patients with T2D are indicated to be*CAPN10*(calpain 10),*KIR6. 2* (potassium inward-rectifier 6.2),*PPAR γ* (peroxisome proliferator-activated receptor *γ*), and*IRS-1*(insulin receptor substrate-1) \[[@B9]\]. Another important understanding of the mechanism underlying T2D is associated with the dysfunction of *β*-cell in human pancreatic islets \[[@B10], [@B11]\]. The decreased *β*-cell mass and increased *β*-cell apoptosis resulted in T2D development and progression. The discovery of novel approaches for T2D treatment has concerned the uncharted area underlying mechanism.

In this work, we downloaded the microarray gene expression data of human pancreatic islets with or without T2D from GEO database. A comprehensive perspective was provided to understand the mechanism underlying T2D with the application of computational bioinformatics method. The dysfunction pathways, potential transcription factor targets, and microRNA targets were explored based on DEGs analysis. Besides, the candidate small molecules were identified, which were capable of ameliorating these genetic changes.

2. Data and Methods {#sec2}
===================

2.1. Affymetrix Microarray Data and Differentially Expressed Genes Analysis {#sec2.1}
---------------------------------------------------------------------------

The cDNA microarray expression data (GSE38642) was downloaded from Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>), which was deposited by Taneera et al. \[[@B4]\]. The gene expression data were collected from human pancreatic islets including 54 nondiabetic samples and 9 T2D samples. As the progression of T2D is strongly associated with HbA1c expression \[[@B4]\], we only selected the 29 samples without T2D (HbA1c expression \< 6.0) in control group and 8 samples with T2D (HbA1c expression \> 6.0) in experimental group. We downloaded the raw data and annotation files for further analysis based on the platform of GPL6244 (Affymetrix Human Gene 1.0 ST Array).

Geoquery software is a tool for analysis and comprehension of microarray and genomics data directly from GEO database \[[@B13]\]. Limma statistics is commonly used for assessing differential expression genes \[[@B14], [@B15]\].

The microarray data was further performed by Geoquery in *R* statistical programming environment \[[@B16]\]. Then the differentially expressed genes between type 2 diabetic islets and nondiabetic islets were analyzed by limma package and were tested by modified *t*-test based on Empirical Bayes Methods \[[@B17]\].

2.2. Pathways Enrichment Analysis of Differentially Expressed Genes {#sec2.2}
-------------------------------------------------------------------

WikiPathways is a public wiki for building research communities on biological pathways, which is characterized for pathway curation and pathway ontology annotations \[[@B18]\]. WebGestalt2 is a gene set analysis toolkit for functional enrichment analysis for large scale of genome \[[@B19]\].

We collected all the metabolic and nonmetabolic pathways from WikiPathways database and performed pathway enrichment analysis with the application of Gene Set Analysis Toolkit V2.

2.3. Prediction of Potential Transcription Factors Targets and MicroRNAs for Differential Expression Genes {#sec2.3}
----------------------------------------------------------------------------------------------------------

Molecular Signatures Database (MSigDB) is freely available (<http://www.broadinstitute.org/gsea/msigdb/index.jsp>) collection of a large scale of well-annotated genomic data \[[@B20]\].

The entire set of transcription factor target gene signatures and microRNA data were obtained from the MSigDB. The gene set enrichment analysis was performed on hypergeometric algorithm. Finally, the potential transcription factors targets and microRNAs were obtained after testing by BH (Barnes-Hut) algorithm.

2.4. The Construction of Regulatory Network {#sec2.4}
-------------------------------------------

We integrated the data of DEGs, potential transcription factor binding sites, and microRNAs obtained in our work and established the regulatory network. And we also constructed a regulatory motif with the DEGs regulated by multiple transcription factors and microRNAs for further analysis.

2.5. Identification of Candidate Small Molecules {#sec2.5}
------------------------------------------------

The connectivity map (CMap) deposited genome-wide transcriptional expression data (7056 gene expression profiles) from 6100 small molecules treatment-control experiments \[[@B21]\].

We firstly divided the DEGs identified in our paper into two groups: upregulated DEGs and downregulated ones and selected the significantly differential expression genes (Top 500) in each group. The gene set enrichment analysis (GSEA) was performed between the significantly differential expressed genes and those from treatment-control pairs in CMap database. Then an enrichment score ranging from −1 to 1 was obtained, which represented the level of similarity. When the positive enrichment score was closed to 1, the corresponding bioactive small molecule (perturbagen) was considered to reversal the expression of query signature in the progression of disease, otherwise the perturbagen contributed to the development of disease.

3. Results {#sec3}
==========

3.1. Identification of Differentially Expressed Genes {#sec3.1}
-----------------------------------------------------

To assess the differentially expressed genes, we downloaded the GSE38642 gene expression profile from GEO database. After analyzed by limma package and *t*-test, we defined *P* \< 0.0001 as the cutoff value. Total 225 genes were identified to be significantly differential expressed between T2D islets tissues and normal tissues.

3.2. Identification of Dysfunction Pathways {#sec3.2}
-------------------------------------------

In order to investigate the DEGs in molecular functional level, we carried out pathway enrichment analysis based on WikiPathways database. Total of 15 pathways were revealed to be significantly dysregulated with *P* \< 0.05 and at least 2 genes enriched.

As shown in [Table 1](#tab1){ref-type="table"}, the enriched pathways terms relevant with cell surface function, signal transduction, hormone regulation, cellular metabolism, and immune response were determined to be dysregulated in the progression of T2D, such as focal adhesion, MAPK signaling pathway, Prostaglandin Synthesis and Regulation, Eicosanoid Synthesis, Mitochondrial LC-Fatty Acid, Beta-Oxidation, Selenium Pathway, Fatty Acid Biosynthesis, Tryptophan metabolism, IL-6 signaling pathway, IL-7 signaling pathway, IL-1 signaling pathway, Inflammatory Response Pathway, and Complement and Coagulation Cascades. Besides, the Integrated Pancreatic Cancer Pathway was also identified to be disturbed in T2D development.

3.3. The Potential Transcription Factor Targets and MicroRNAs {#sec3.3}
-------------------------------------------------------------

The changes in the patterns of gene expression were affected by transcriptional regulation and posttranscriptional regulation; so we predicted the potential transcription factor targets and microRNA targets to further explore the mechanism underlying T2D progression.

After investigation by hypergeometric and BH algorithm, we defined *P* \< 10^−10^ and *P* \< 10^−6^ as threshold values in transcription factor targets analysis and microRNAs targets analysis, respectively.

As shown in [Table 2](#tab2){ref-type="table"}, the enrichment transcription factor targets were explored based on the upstream sequences of DEGs. And the significant microRNAs and targets uncovered in this work were listed in [Table 3](#tab3){ref-type="table"}.

3.4. The Regulatory Network Construction {#sec3.4}
----------------------------------------

To investigate the associations between DEGs and microRNAs, transcription factors, we constructed the regulatory network. As shown in [Figure 1](#fig1){ref-type="fig"}, different DEGs were regulated by different microRNAs and transcription factors. The DEGs involved with multiple regulators might play key roles in the progression of T2D; therefore we selected the DEGs corresponding to multiple microRNAs and transcription factors (*n* ≥ 20) to establish the regulatory motif. [Figure 2](#fig2){ref-type="fig"} showed that 5 genes played critical roles in the T2D development, including*ZADH2, BTBD3, LTBP1*,*PDGFRA,*and*FST*.

3.5. Identification of Candidate Small Molecules {#sec3.5}
------------------------------------------------

We performed computational bioinformatics analysis to identify the candidate drugs for T2D treatment. After comparing the query signatures induced by DEGs with data from CMap database, a large amount of small molecules was identified, which had positive or negative correlation to query signature. The top 20 small molecules closely relevant with T2D were listed in [Table 4](#tab4){ref-type="table"}. The small molecules with higher positive enrichment scores were determined to be sanguinarine (enrichment score = 0.977) and DL-thiorphan (enrichment score = 0.956). In addition, small molecule of felbinac showed highly significant negative score (enrichment = −0.847).

4. Discussion {#sec4}
=============

Nowadays, T2D is highlighted by its increasing epidemicity all over the word \[[@B3]\]. Although numerous studies have been conducted concerning the therapies for T2D, the effective approaches for T2D treatment are relatively rare. The current work provided the foundational evidences for T2D development with systematic informatics analysis. In this paper, we downloaded the microarray gene expression data (GSE38642) from GEO database and identified the DEGs between diabetic and nondiabetic human islets. Results showed that, using the cutoff value of *P* \< 0.0001, total 225 genes were differentially expressed. By pathway enrichment analysis of the DEGs, 15 pathways were revealed to be significantly dysregulated such as Eicosanoid Synthesis, Prostaglandin Synthesis and Regulation, and Integrated Pancreatic Cancer Pathway.

Eicosanoid is a critical signaling molecules biological process and played diverse and complex roles in biological and pathological control \[[@B22]\]. Eicosanoids consist of multiple subfamilies including prostaglandins, thromboxanes, leukotrienes, and derivatives of arachidonate \[[@B23]\]. Many diseases such as cardiovascular disease \[[@B24]\], inflammatory bowel disease \[[@B25]\], and diarrhoeal diseases \[[@B26]\] were mediated by the secretion of eicosanoids. As outlined in previous study, eicosanoids played key roles in modulating platelet function of T2D patients. Thromboxane, served as a member of eicosanoid family, can induce platelet aggregation to vascular endothelium resulting in platelet dysfunction \[[@B27]\]. Platelet aggregation suppressed the normal interaction of intact healthy vascular endothelium with platelets, which might result in macrovascular and microvascular events T2D patients.

Prostaglandin is also a member of eicosanoids, deriving from unsaturated fatty acids \[[@B28]\]. The renal production of prostaglandins has been reported to be associated with nephropathy in T2D \[[@B29]\]. The expression of prostaglandins and their corresponding receptors induced in islets is revealed to be contributors of T2D development \[[@B30]\]. The expression of prostaglandin E2 (PGE2) was elevated, which was positively related with the activation of prostaglandin E receptor 3 (EP3). The activation of PGE2-to-EP3 signaling pathway resulted in the decline of the cAMP activation and insulin secretion induced by glucose. The accumulation of EP3 and PGE2 production contributed to T2D development and *β*-cell dysfunction. Thus, the pathways related with Eicosanoid Synthesis and Prostaglandin Synthesis and Regulation played crucial roles in T2D development and progression. Besides, Integrated Pancreatic Cancer Pathway was also indicated to be a significant pathway in T2D development. Although there were few evidences concerning the association between T2D and integrated pancreatic cancer, it implied that T2D might be a precipitating factor for patients suffering from integrated pancreatic cancer.

Our results also showed that the genes of*LTBP1*,*PDGFRA*, and*FST*were the most significant targets for potential transcription factors and microRNAs. Among these significant targets,*LTBP1*encoded for latent-transforming growth factor beta binding protein 1 which is a member of carrier proteins \[[@B31]\]. LTBP1 has various interactions with extracellular matrix proteins and TGF-beta (TGF-*β*) \[[@B32]\]. TGF-*β* signaling pathway showed tightly association with diabetes development. It is reported that the level of glucose has a direct effect on TGF-*β* activation \[[@B33]\]. An elevated expression of TGF-*β* was observed in serum of patients with T2D and antidiabetic treatment was able to reverse this trend \[[@B34]\]. Another report suggested that the suppression of TGF-*β*-TGF-*β* receptor interaction is available for preventing diabetes progression by inhibiting the differentiation of islet-reactive CD8^+^ T cells in type 1 diabetes \[[@B35]\]. By pathway enrichment analysis, our results also showed that TGF-*β* signaling pathway was significant in the T2D progression.

In addition,*PDGFRA* encoded alpha-type platelet-derived growth factor receptor is one of the latent TGF-beta binding proteins \[[@B36]\]. The production of*PDGFR* is considered to be interacted with PI3K p85*α* and PI3Kp85*α*pY580 is activated by insulin receptor tyrosine kinase \[[@B37]--[@B39]\].*FST* is the gene for follistatin which also served as activin-binding protein. Follistatin generally exists in blood and is considered to be involved in the inflammatory response stimulated by tissue injury or pathogenic incursion. Despite the clarification of mechanism underlying T2D concerning*PDGFRA* and*FST* was far from being clear, the significant nodes in regulatory networks may be potential drug targets for T2D treatment.

Besides, another important implication in our work was the identification of a group of small molecules. Data in [Table 4](#tab4){ref-type="table"} showed that the small molecules of sanguinarine (enrichment = 0.977) and DL-thiorphan (enrichment = 0.956) showed highly significant positive scores, suggesting that these small molecules are candidate agents targeting for T2D.

Sanguinarine is a benzophenanthridine alkaloid, which has been ascribed to a novel bioactive component extracted from plants \[[@B40]\]. And it has showed various properties including antimicrobial, antioxidant, and anti-inflammatory \[[@B41]\]. Previous researches proved that sanguinarine possessed potent anticancer activity against many different tumors, such as gastric osteosarcoma adenocarcinoma \[[@B42]\], osteosarcoma \[[@B43]\], prostate tumor \[[@B44]\], and oral cancers \[[@B45]\]. Sanguinarine prevented the development of cancers by inducing cancer cell apoptosis, suppressing tumor growth, migration, and invasion \[[@B46], [@B47]\]. A present study revealed that sanguinarine is involved in cell migration and angiogenesis suppression in cancer development by inhibiting the activity of vascular endothelial growth factor (VEGF) \[[@B40]\]. In spite of the increasing studies highlighting the anticancer property of sanguinarine, reviews also indicated the sanguinarine antidiabetic activity \[[@B48]\]. Sanguinarine derived from*Fumaria parviflora* plants has a hypoglycemic effect. In addition, sanguinarine has been used as an important drug against infections in one or more countries worldwide \[[@B49]\]. Moreover, DL-thiorphan is served as the specific neutral endopeptidase (NEP) inhibitor, which is widely used to differentiate NEP enzyme activity. NEP enzyme is a membrane-bound metallopeptidase that plays key roles in wound repair \[[@B50]\]. Fatty acids and glucose stimulated the expression of NEP. The activity of NEP was increased in the skin of objects with diabetic wound \[[@B51]\]. However, there are insufficient evidences indicating DL-thiorphan can be directly used in glucose control for patients with T2D. Therefore, sanguinarine and DL-thiorphan may be candidate agents for diabetes treatment in the near future.

In summary, the present study provides a systematic understanding for the mechanism underlying T2D development. The significant nodes such as*LTBP1*,*PDGFRA*, and*FST* assessed in regulatory network may be drug targets for T2D treatment. And sanguinarine and DL-thiorphan may be candidate agents targeting for T2D. However, more studies are required to confirm these discoveries in our work.
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###### 

Dysfunction pathways between human T2D islet cells and normal islet cells.

  Pathway                                      Count   *P* value
  -------------------------------------------- ------- -----------
  Eicosanoid synthesis                         3       0.0016
  MAPK signaling pathway                       7       0.0029
  IL-6 signaling pathway                       4       0.005
  Integrated Pancreatic Cancer Pathway         7       0.0055
  Mitochondrial LC-Fatty Acid Beta-Oxidation   2       0.0152
  Complement and Coagulation Cascades          3       0.0205
  Focal adhesion                               6       0.021
  Selenium Pathway                             4       0.0316
  IL-7 signaling pathway                       2       0.0354
  TGF-beta signaling pathway                   3       0.0362
  IL-1 signaling pathway                       3       0.0377
  Fatty Acid Biosynthesis                      2       0.0436
  Tryptophan metabolism                        3       0.0441
  Inflammatory Response Pathway                2       0.0464
  Prostaglandin Synthesis and Regulation       2       0.0494

###### 

Potential transcription factor targets.

  TF target                      *P* value      TF target                      *P* value
  ------------------------------ -------------- ------------------------------ -----------
  hsa_V\$RP58_01                 9.61*E* − 05   hsa_V\$SRF_Q6                  0.0192
  hsa_GGARNTKYCCA_UNKNOWN        0.0002         hsa_V\$PITX2_Q2                0.0201
  hsa_TTGTTT_V\$FOXO4_01         0.0008         hsa_V\$IRF_Q6                  0.0201
  hsa_V\$CART1_01                0.0009         hsa_V\$HNF1_C                  0.0205
  hsa_RYTGCNWTGGNR_UNKNOWN       0.0019         hsa_V\$CEBPA_01                0.0205
  hsa_TTAYRTAA_V\$E4BP4_01       0.0021         hsa_GGGNNTTTCC_V\$NFKB_Q6_01   0.0209
  hsa_V\$NFKB_Q6                 0.0024         hsa_V\$TAL1BETAE47_01          0.0209
  hsa_RYAAAKNNNNNNTTGW_UNKNOWN   0.0027         hsa_V\$CMYB_01                 0.0214
  hsa_V\$NFKB_C                  0.0027         hsa_V\$HLF_01                  0.0214
  hsa_TATAAA_V\$TATA_01          0.0041         hsa_V\$CDC5_01                 0.0218
  hsa_V\$CEBP_Q2                 0.0052         hsa_V\$TAL1ALPHAE47_01         0.0223
  hsa_CTTTAAR_UNKNOWN            0.0054         hsa_V\$RSRFC4_01               0.0223
  hsa_V\$FOXJ2_02                0.0057         hsa_V\$CEBP_Q3                 0.0232
  hsa_V\$SMAD3_Q6                0.0058         hsa_V\$ICSBP_Q6                0.0252
  hsa_TGGAAA_V\$NFAT_Q4_01       0.0063         hsa_V\$ZID_01                  0.0267
  hsa_CAGGTA_V\$AREB6_01         0.0064         hsa_CCCNNNNNNAAGWT_UNKNOWN     0.0269
  hsa_YTAAYNGCT_UNKNOWN          0.0071         hsa_V\$RORA2_01                0.0291
  hsa_V\$FREAC4_01               0.0079         hsa_CAGGTG_V\$E12_Q6           0.0293
  hsa_V\$ER_Q6_02                0.0084         hsa_V\$GATA6_01                0.031
  hsa_V\$CEBPB_02                0.0092         hsa_V\$E4BP4_01                0.0315
  hsa_AAAYRNCTG_UNKNOWN          0.0096         hsa_V\$CREB_Q4_01              0.0321
  hsa_TAATTA_V\$CHX10_01         0.0101         hsa_V\$IK2_01                  0.0328
  hsa_TTANTCA_UNKNOWN            0.0106         hsa_V\$CRX_Q4                  0.0334
  hsa_V\$HNF4ALPHA_Q6            0.0113         hsa_GGATTA_V\$PITX2_Q2         0.0347
  hsa_V\$ER_Q6_01                0.0118         hsa_V\$ER_Q6                   0.0352
  hsa_CTGCAGY_UNKNOWN            0.0129         hsa_V\$RSRFC4_Q2               0.0364
  hsa_RNGTGGGC_UNKNOWN           0.0133         hsa_V\$TATA_C                  0.0371
  hsa_V\$HP1SITEFACTOR_Q6        0.0134         hsa_V\$FAC1_01                 0.0378
  hsa_TGANTCA_V\$AP1_C           0.0141         hsa_YKACATTT_UNKNOWN           0.0384
  hsa_TGTYNNNNNRGCARM_UNKNOWN    0.0153         hsa_V\$GATA1_05                0.0412
  hsa_V\$HNF1_01                 0.018          hsa_WGTTNNNNNAAA_UNKNOWN       0.0413
  hsa_CTTTGA_V\$LEF1_Q2          0.0183         hsa_GTGGGTGK_UNKNOWN           0.0485

###### 

Potential microRNA targets.

  Target sequence   MicroRNAs                                                                *P* value
  ----------------- ------------------------------------------------------------------------ -----------
  hsa_TATTATA       MIR-374                                                                  0.0018
  hsa_TGAATGT       MIR-181A, MIR-181B, MIR-181C, MIR-181D                                   0.0068
  hsa_TTGCACT       MIR-130A, MIR-301, MIR-130B                                              0.0069
  hsa_GGGACCA       MIR-133A, MIR-133B                                                       0.0139
  hsa_ATGTCAC       MIR-489                                                                  0.016
  hsa_TGCTGCT       MIR-15A, MIR-16, MIR-15B, MIR-195, MIR-424, MIR-497                      0.0174
  hsa_GTTTGTT       MIR-495                                                                  0.0209
  hsa_TACTTGA       MIR-26A, MIR-26B                                                         0.0245
  hsa_GACAATC       MIR-219                                                                  0.0262
  hsa_GTGTTGA       MIR-505                                                                  0.0269
  hsa_TCATCTC       MIR-143                                                                  0.0269
  hsa_ATACTGT       MIR-144                                                                  0.0283
  hsa_GTACTGT       MIR-101                                                                  0.0283
  hsa_CCCAGAG       MIR-326                                                                  0.0322
  hsa_CTACCTC       LET-7A, LET-7B, LET-7C, LET-7D, LET-7E, LET-7F, MIR-98, LET-7G, LET-7I   0.0346
  hsa_ATAAGCT       MIR-21                                                                   0.0391
  hsa_CACCAGC       MIR-138                                                                  0.0393
  hsa_TTTGTAG       MIR-520D                                                                 0.0394
  hsa_CACTGTG       MIR-128A, MIR-128B                                                       0.0419
  hsa_ACTGTGA       MIR-27A, MIR-27B                                                         0.0426
  hsa_AAGTCCA       MIR-422B, MIR-422A                                                       0.0458

###### 

Top 20 significant small molecules.

  CMap name              Enrichment   *P*
  ---------------------- ------------ ---------
  8-Azaguanine           0.932        0.00004
  Apigenin               0.86         0.00052
  Chrysin                0.931        0.00056
  Sulfametoxydiazine     0.855        0.00056
  Lycorine               0.803        0.00068
  Digoxin                0.846        0.0008
  Prochlorperazine       0.467        0.00086
  Sanguinarine           0.977        0.00087
  Helveticoside          0.733        0.00097
  Felbinac               −0.847       0.00101
  Adiphenine             −0.771       0.00118
  Diloxanide             −0.83        0.00157
  Etiocholanolone        −0.704       0.00157
  Heptaminol             −0.753       0.0017
  Acetylsalicylic acid   0.499        0.00174
  Proscillaridin         0.903        0.00182
  Cinchonine             −0.82        0.00197
  0316684-0000           −0.813       0.00229
  Proadifen              0.806        0.00265
  DL-Thiorphan           0.956        0.00342
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